J&J mulls the future of its med tech biz; Baxano raises $10M;

@FierceMedDev: Lombard Medical revives stateside IPO plans with a $55M debut. Article | Follow @FierceMedDev

@VarunSaxena2: BREAKING: Zimmer buying fellow orthopedics company Biomet for $13.35 billion. | Follow @VarunSaxena2

@EmilyWFierce: New genetic-bionic treatment for hearing loss could help improve pitch perception in those with cochlear implants. Article from Wired | Follow @EmilyWFierce

@MichaelGFierce: X-ray-activated nanoparticles release cancer-killing light deeper into tissue. More from FierceDrugDelivery | Follow @MichaelGFierce

> After signing a deal to sell off its diagnostics business for $4.2 billion, Johnson & Johnson ($JNJ) is planning to sit down with investors next month and review the future of its med tech holdings. More

> Invacare ($IVC) is still working to get out from under an FDA consent decree blocking manufacturing at one of its U.S. facilities. News

> Baxano Surgical ($BAXS) raised $10 million in a private placement. Story

Biotech News

@FierceBiotech: An international biotech tackles CRISPR gene editing tech with $25M bankroll. More | Follow @FierceBiotech

@JohnCFierce: You gotta give $AZN credit. They keep spinning. Beefing up PhIII, which should have been Soriot's initial focus. More from the FT | Follow @JohnCFierce

@DamianFierce: $CELG opens down 5%. Perhaps a $710M deal didn't thrill investors who just watched R&D costs drag profits. | Follow @DamianFierce

@EmilyMFierce: Genetically engineered mosquitoes could be vital weapon against malaria. More from The Guardian | Follow @EmilyMFierce

> Hyperion bets up to $570M on diabetes biotech Andromeda. More

> AstraZeneca continues to chop back, spotlights immuno-oncology PhIII. Report

> J&J snags FDA OK for rare blood disorder drug siltuximab. Article

Pharma News

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: Novartis, GSK team up in consumer JV to save big money, gain big scale. More | Follow @TracyStaton

@EricPFierce: Gilead turns in eye-popping results because of huge sales of Sovaldi, $2.3B in Q1 sales for the hep C drug. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Allergan poison pill presages a battle against Valeant's $47B takeover. Story | Follow @CarlyHFierce

> No big thrill from Novartis in Q1, just a 'solid' $14B in sales. News

> AstraZeneca CEO jumps into asset-sale fray to 'focus on what we do well.' Report

> Pfizer concedes Celebrex to Actavis, Teva after 2015 patent strike-down. Story

Pharma Manufacturing News

> FDA is now reporting recalls still awaiting classification. News

> China's Sinovac gets $9.6M grant to build vaccine plant. Article

> Report: Industry's regulatory-centric focus for manufacturing will no longer cut it. More

> Bristol-Myers extends manufacturing pact with Samsung. Story

> Wockhardt smacked by state regulator in India. Report

> Regulatory issues crush India's drug export growth. Item

Vaccines News

> Sinovac scores $9.6M Chinese grant for new hand, foot and mouth disease vaccine. Article

> Tetanus shot stored at higher temperatures as effective as cold chain-stored jab. More

> Immune discovery puts vaccine for H. pylori closer in sight. Story

> MERS vaccine to ease outbreak within 6 months, virologist says. Item

> Novartis bids farewell to vaccines with $7.1B sale to GSK. News

> U.K. health secretary asks Novartis CEO for Bexsero price cut. Report

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.